Q5155 Injection, aflibercept-jbvf, 1 milligrams
Also known as: aflibercept biosimilar, Fabhalta, anti-VEGF, VEGF inhibitor
Injection of aflibercept-jbvf (Fabhalta), a biosimilar to aflibercept, administered at 1 milligram per dose.
In Plain Language
eye injection; age-related macular degeneration treatment; vision therapy
Clinical Context
Used for neovascular age-related macular degeneration with intravitreal administration every 4-8 weeks. Inhibits angiogenesis in retinal disease.
RVU Information
CPT Q5155 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5155?
CPT Q5155 (Injection, aflibercept-jbvf, 1 milligrams) is a Q Codes code. Injection of aflibercept-jbvf (Fabhalta), a biosimilar to aflibercept, administered at 1 milligram per dose.
Is Q5155 covered by insurance?
Q5155 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for neovascular age-related macular degeneration with intravitreal administration every 4-8 weeks. Inhibits angiogenesis in retinal disease.
When is CPT Q5155 used?
Used for neovascular age-related macular degeneration with intravitreal administration every 4-8 weeks. Inhibits angiogenesis in retinal disease.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.